Advertisement

Experience with the Use of Nilotinib in Indian Patients

  • Avaronnan Manuprasad
  • Prasanth GanesanEmail author
  • Trivadi S. Ganesan
  • Venkatraman Radhakrishnan
  • Manikandan Dhanushkodi
  • Samson Mani
  • Tenali Gnana Sagar
Original Article

Abstract

Important genetic and ethnic factors could affect the toxicity and efficacy of tyrosine kinase inhibitors. Though nilotinib has been available in India since 2010, there is no report on its safety and toxicity from Indian patients with chronic myeloid leukemia. This is an analysis of efficacy and toxicity of nilotinib when used as a second line drug after failure or intolerance to imatinib. Thirty-seven patients started nilotinib [median age 46 years, median duration from diagnosis 5 years, 73% in chronic phase at time of switch] between 2010 to 2016. Reason for switch: failure of imatinib in 33 (89%) and intolerance in 4 (11%). Starting dose 600 mg/day. Dose modifications: 15 (40%) patients required initial dose modifications, but subsequently 25 (67%) patients could tolerate 600 mg/day. Nine (24%) patients were able to tolerate 800 mg/day. The commonest grade 3/4 toxicities were thrombocytopenia (n = 9, 24%), hyperbilirubinemia (n = 7, 18%) and leukopenia (n = 3, 8%). Six patients (16%) discontinued nilotinib due to toxicity while 8 (21%) stopped due to lack of efficacy. After a median duration of 14 months among those continuing nilotinib, 54% of patients responded which included 14 patients who achieved CHR and seven who achieved major molecular response. In the first report on use of nilotinib in Indian patients, we observed a higher incidence of liver toxicity compared to previous reports. This should be seen the context that all these patients received nilotinib as second line therapy.

Keywords

Chronic myeloid leukemia Nilotinib Second line therapy India Toxicity 

Notes

Compliance with Ethical Standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional/national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

This is a retrospective study and all patients received standard treatment. For this type of study formal consent is not required as per our ethical committee policy.

References

  1. 1.
    Ganesan P, Kumar L (2016) Chronic myeloid leukemia in India. J Glob Oncol (internet). http://jgo.ascopubs.org/content/early/2016/07/15/JGO.2015.002667.abstract
  2. 2.
    Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, Teo ASM et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18(4):521–528CrossRefPubMedGoogle Scholar
  3. 3.
    Wang J, Shen Z-X, Saglio G, Jin J, Huang H, Hu Y et al (2015) Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood (internet). http://www.bloodjournal.org/content/early/2015/03/12/blood-2014-09-601674.abstract
  4. 4.
    Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540–3546CrossRefPubMedGoogle Scholar
  7. 7.
    Nicolini FE, Turkina A, Shen Z-X, Gallagher N, Jootar S, Powell BL et al (2012) Expanding nilotinib access in clinical trials (ENACT). Cancer 118(1):118–126CrossRefPubMedGoogle Scholar
  8. 8.
    Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259CrossRefPubMedGoogle Scholar
  9. 9.
    Hussain S, Usman Shaikh M (2015) Response and adverse effects of nilotinib in imatinib-resistant chronic myeloid leukemia patients: data from a developing country. Clin Ther 37(11):2449–2457Google Scholar
  10. 10.
    Gusarova G, Chelysheva EY, Turkina AG (2013) Long-term results and adverse events of second line nilotinib therapy after imatinib failure in patients with chronic myeloid leukemia in chronic phase in clinical practice. Blood 122(21):5181Google Scholar
  11. 11.
    Valent P, Hadzijusufovic E, Schernthaner G-H, Wolf D, Rea D, le Coutre P (2015) Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125(6):901–906CrossRefPubMedGoogle Scholar
  12. 12.
    Chakraborty K, Bossaer J, Patel R, Krishnan K (2013) Successful treatment of nilotinib-induced pleural effusion with prednisone. J Oncol Pharm Pract 19(2):175–177CrossRefPubMedGoogle Scholar
  13. 13.
    Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ (2013) Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib—a retrospective chart review analysis. Curr Med Res Opin 29(6):623–631. doi: 10.1185/03007995.2013.789012 CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2017

Authors and Affiliations

  1. 1.Department of Medical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Department of Molecular OncologyCancer Institute (WIA)ChennaiIndia

Personalised recommendations